专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明授权

US07384948B2 Piperidine derivatives useful as CCR5 antagonists 失效
标题翻译：哌啶衍生物可用作CCR5拮抗剂
公开(公告)号：US07384948B2
公开(公告)日：2008-06-10
申请号：US10628933
申请日：2003-07-29
申请人： Anandan Palani , Michael W. Miller , Jack D. Scott
发明人： Anandan Palani , Michael W. Miller , Jack D. Scott
IPC分类号： A61K31/505 , C07D401/14
CPC分类号： C07D401/14
摘要： The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
摘要翻译：本发明提供下式的化合物或其药学上可接受的盐或溶剂化物，其中R 1，R 2，R 3，R 3， A，B和B如本说明书中所定义。本发明还提供含有本发明化合物的药物组合物和使用本发明化合物的治疗方法。本发明还涉及本发明化合物与一种或多种可用于治疗人类免疫缺陷病毒（HIV）的抗病毒剂或其它药剂的组合的用途。本发明还涉及本发明化合物单独或与另一种药剂组合用于治疗实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化。

92. 发明授权

US07045636B2 MCH antagonists for the treatment of obesity 失效
公开(公告)号：US07045636B2
公开(公告)日：2006-05-16
申请号：US10278468
申请日：2002-10-23
申请人： Anandan Palani , Sherry A. Shapiro , Mark D. McBriar , Jing Su
发明人： Anandan Palani , Sherry A. Shapiro , Mark D. McBriar , Jing Su
IPC分类号： C07D207/00 , C07D213/00 , A01N43/40 , A61K31/435
CPC分类号： C07D295/13 , A61K38/00 , C07C255/60 , C07C2601/02 , C07C2601/08 , C07D205/04 , C07D207/12 , C07D207/14 , C07D295/15 , C07K5/06026 , C07K5/06139 , C07K5/06191
摘要： The present invention discloses compounds, which are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

93. 发明授权

US06689765B2 Piperazine derivatives useful as CCR5 antagonists 有权
标题翻译：可用作CCR5拮抗剂的哌嗪衍生物
公开(公告)号：US06689765B2
公开(公告)日：2004-02-10
申请号：US10061011
申请日：2002-01-30
申请人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
发明人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
IPC分类号： A61K31695
CPC分类号： C07D401/06 , A61K31/496 , A61K45/06 , C07D211/58 , C07D401/10 , C07D401/12 , C07D405/12 , C07D409/06 , C07D413/06 , A61K2300/00
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v, host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译：使用下式的CCR5拮抗剂或其药学上可接受的盐，其中R是任选取代的苯基，吡啶基，噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基，取代的杂芳基，萘基，芴基，苯基烷基，萘基，萘基烷基，杂芳基或杂芳基烷基; R 4，R 5，R 5和R 5独立地选自氢，烷基，烷氧基烷基，环烷基，环烷基烷基或任选取代的苯基， R 7为氢或烷基; R 6为氢，烷基或烯基;用于治疗HIV，实体器官移植排斥，移植物v，宿主病，关节炎，类风湿性关节炎，炎性肠病，特应性皮炎，公开了牛皮癣，哮喘，过敏或多发性硬化，以及新化合物，包含它们的药物组合物，以及本发明的CCR5拮抗剂与用于治疗可用于治疗炎性疾病的HIV或药物。

94. 发明公开

US20230285514A1 STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS 审中-公开
公开(公告)号：US20230285514A1
公开(公告)日：2023-09-14
申请号：US17785279
申请日：2020-12-18
申请人： Elisabetta BIANCHI , Paul E. CARRINGTON , Qiaolin DENG , Songnian LIN , Federica ORVIETO , Anandan PALANI , Antonello PESSI , Tomi K. SAWYER , Merck Sharp & Dohme LLC
发明人： Elisabetta Bianchi , Paul E. Carrington , Qiaolin Deng , Songnian Lin , Federica Orvieto , Anandan Palani , Antonello Pessi , Tomi K. Sawyer
IPC分类号： A61K38/26 , A61K38/28 , C07K14/605
CPC分类号： A61K38/26 , A61K38/28 , C07K14/605
摘要： The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

95. 发明授权

US10493125B2 Co-agonists of the glucagon and GLP-1 receptors 有权
公开(公告)号：US10493125B2
公开(公告)日：2019-12-03
申请号：US15774622
申请日：2016-12-05
申请人： Merck Sharp & Dohme Corp. , Anandan Palani , Paul E. Carrington , Antonello Pessi , Armin Lahm , Elisabetta Bianchi , Anna Demartis
发明人： Anandan Palani , Paul E. Carrington , Antonello Pessi , Armin Lahm , Elisabetta Bianchi , Anna Demartis
IPC分类号： A61K38/16 , C07K14/575 , A61P1/16 , A61P3/10 , A61K38/00
CPC分类号： A61K38/16 , A61P1/16 , A61P3/10 , C07K14/575 , A61K38/00
摘要： Co-agonists of the glucagon and GLP-1 receptors are described.

96. 发明授权

US09549917B2 Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases 有权
标题翻译：杂环取代的苯并呋喃衍生物及其用于治疗病毒性疾病的方法
公开(公告)号：US09549917B2
公开(公告)日：2017-01-24
申请号：US14343448
申请日：2012-08-16
申请人： Casey C. McComas , Nigel J. Liverton , Joerg Habermann , Uwe Koch , Frank Narjes , Peng Li , Xuanjia Peng , Richard Soll , Hao Wu , Anandan Palani , Xing Dai , Hong Liu , Shuwen He , Zhong Lai , Qun Dang , Nicolas Zorn
发明人： Casey C. McComas , Nigel J. Liverton , Joerg Habermann , Uwe Koch , Frank Narjes , Peng Li , Xuanjia Peng , Richard Soll , Hao Wu , Anandan Palani , Xing Dai , Hong Liu , Shuwen He , Zhong Lai , Qun Dang , Nicolas Zorn
IPC分类号： A61K45/06 , A61K31/506 , A61K31/444 , A61K31/443 , A61K31/497 , A61K31/501 , A61K31/695 , A61K31/424 , A61K31/4245 , A61K31/4439 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D498/04 , C07D513/04 , A61K31/433 , A61K31/5365 , A61K31/5377 , A61K31/5383 , C07F7/10
CPC分类号： A61K31/4245 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5365 , A61K31/5377 , A61K31/5383 , A61K31/695 , A61K45/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/04 , C07D513/04 , C07F7/10 , Y02A50/385 , Y02A50/387 , Y02A50/389 , A61K31/424 , A61K2300/00
摘要： The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
摘要翻译：本发明涉及可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5B聚合酶活性用于治疗或预防HCV感染的式（I）化合物并用于在基于细胞的系统中抑制HCV病毒复制和/或病毒生产。

97. 发明授权

US08889683B2 Substituted quinoxalines as inhibitors of fatty acid binding protein 有权
标题翻译：取代喹喔啉作为脂肪酸结合蛋白的抑制剂
公开(公告)号：US08889683B2
公开(公告)日：2014-11-18
申请号：US13242426
申请日：2011-09-23
申请人： Clifford Cheng , Gerald W. Shipps, Jr. , Xiaohua Huang , Ying Huang , Ning Shao , Ashwin Rao , Anandan Palani , Peter Orth , Johannes H. Voigt , Robert J. Herr , Lana Michele Rossiter , Qi Zeng , Xianfeng Sun
发明人： Clifford Cheng , Gerald W. Shipps, Jr. , Xiaohua Huang , Ying Huang , Ning Shao , Ashwin Rao , Anandan Palani , Peter Orth , Johannes H. Voigt , Robert J. Herr , Lana Michele Rossiter , Qi Zeng , Xianfeng Sun
IPC分类号： A61K31/498 , C07D241/44 , C07D401/14 , C07D403/14 , C07D413/06 , C07D401/06 , C07D403/12 , C07D403/06
CPC分类号： C07D403/06 , C07D241/44 , C07D401/06 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/06
摘要： The present invention relates to novel quinoxaline compounds of Formula I: as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
摘要翻译：本发明涉及式I的新型喹喔啉化合物：作为脂肪酸结合蛋白（“FABP”）抑制剂，包含喹喔啉化合物的药物组合物和喹喔啉化合物用于治疗或预防心血管疾病，代谢紊乱，肥胖症或肥胖相关疾病，糖尿病，血脂异常，糖尿病并发症，葡萄糖耐量降低或空腹血糖受损。

98. 发明授权

US08034933B2 Piperidine derivatives useful as CCR5 antagonists 失效
标题翻译：哌啶衍生物可用作CCR5拮抗剂
公开(公告)号：US08034933B2
公开(公告)日：2011-10-11
申请号：US12104914
申请日：2008-04-17
申请人： Anandan Palani , Michael W. Miller , Jack D. Scott
发明人： Anandan Palani , Michael W. Miller , Jack D. Scott
IPC分类号： C07D401/14 , C07D239/02
CPC分类号： C07D401/14
摘要： The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
摘要翻译：本发明提供下式化合物或其药学上可接受的盐或溶剂化物，其中R1，R2，R3，R9，R10，A和B如说明书中所定义。本发明还提供含有本发明化合物的药物组合物和使用本发明化合物的治疗方法。本发明还涉及本发明化合物与一种或多种可用于治疗人类免疫缺陷病毒（HIV）的抗病毒剂或其它药剂的组合的用途。本发明还涉及本发明化合物单独或与另一种药剂组合用于治疗实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化。

99. 发明授权

US07442703B2 Piperidine derivatives useful as CCR5 antagonists 失效
公开(公告)号：US07442703B2
公开(公告)日：2008-10-28
申请号：US10629466
申请日：2003-07-29
申请人： Anandan Palani , Michael W. Miller , Jack D. Scott
发明人： Anandan Palani , Michael W. Miller , Jack D. Scott
IPC分类号： A61K31/505 , C07D401/14
CPC分类号： C07D401/14
摘要： The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.

100. 发明申请

US20080188485A1 PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS 有权
标题翻译：哌啶衍生物作为CCR5拮抗剂有用
公开(公告)号：US20080188485A1
公开(公告)日：2008-08-07
申请号：US12055900
申请日：2008-03-26
申请人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
发明人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
IPC分类号： A61K31/496 , A61P1/00 , A61P19/02
CPC分类号： C07D401/06 , A61K31/496 , A61K45/06 , C07D211/58 , C07D401/10 , C07D401/12 , C07D405/12 , C07D409/06 , C07D413/06 , A61K2300/00
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译：使用下式的CCR5拮抗剂或其药学上可接受的盐，其中R是任选取代的苯基，吡啶基，噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基，取代的杂芳基，芴基，二苯甲基或任选取代的苯基或杂芳基烷基; R 3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基或任选取代的苯基，苯基烷基，萘基，萘基烷基，杂芳基或杂芳基烷基; R 4，R 5和R 7是氢或烷基; R 6是氢，烷基或链烯基; 公开了用于治疗HIV，实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化的新型化合物，以及包含它们的药物组合物，以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式